Clinical Trial: Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07342244) titled 'Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia' on Dec. 16, 2025.

Brief Summary: This study aims to evaluate whether an innovative combination therapy (CLL1 CAR-T sequential allogeneic hematopoietic stem cell transplantation) is safe, feasible and effective for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML).

Study Start Date: Jan. 30

Study Type: INTERVENTIONAL

Condition: AML AML (Acute Myeloid Leukemia)

Intervention: DRUG: CLL1 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplan...